Developing targeted therapies to prevent cancer spread
Phenotypic marker-guided development of selective antimetastasis therapeutic leads
['FUNDING_R01'] · NORTHWESTERN UNIVERSITY AT CHICAGO · NIH-10892829
This study is looking at how cancer spreads in the body and aims to find new ways to create better treatments that can help patients live longer by targeting the specific markers that show how likely a cancer is to spread.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | NORTHWESTERN UNIVERSITY AT CHICAGO (nih funded) |
| Locations | 1 site (CHICAGO, UNITED STATES) |
| Trial ID | NIH-10892829 on ClinicalTrials.gov |
What this research studies
This research focuses on understanding the complex processes that allow cancer to spread, known as metastasis. By identifying specific cellular structures that indicate a cancer's potential to metastasize, the researchers aim to develop new anti-cancer drugs that are more effective than current treatments. The approach involves using these unique cellular markers to guide the development of therapies that can better target and inhibit the spread of cancer cells. Patients may benefit from more effective treatments that improve long-term survival rates.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with aggressive forms of cancer that have a high risk of metastasis.
Not a fit: Patients with early-stage cancers that are not expected to metastasize may not receive benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective therapies that significantly reduce cancer metastasis and improve patient survival.
How similar studies have performed: Previous research has shown promise in targeting specific cellular markers for cancer treatment, suggesting that this approach could lead to significant advancements in cancer therapy.
Where this research is happening
CHICAGO, UNITED STATES
- NORTHWESTERN UNIVERSITY AT CHICAGO — CHICAGO, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: HUANG, SUI — NORTHWESTERN UNIVERSITY AT CHICAGO
- Study coordinator: HUANG, SUI
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: Anti-Cancer Agents, Breast Cancer